DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lumigan (Bimatoprost) - Summary

 
 



LUMIGAN SUMMARY

LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is a synthetic prostamide analog with ocular hypotensive activity.

LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.


See all Lumigan indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Lumigan (Bimatoprost)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. [2014]
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence

Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. [2013]
Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy... Bimatoprost was found to be well tolerated over the 1-year treatment period.

Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. [2012]
topical administration to upper eyelid margins... CONCLUSION: Bimatoprost 0.03% was found to be effective at enhancing eyelashes in

Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. [2011.10]
PURPOSE: To evaluate bimatoprost versus latanoprost and timolol fixed combination (LTFC) over the 24-hour diurnal curve in patients who switched from timolol... CONCLUSIONS: The LTFC and bimatoprost therapies were equally effective in maintaining IOP at lower levels during the 24-hour period in patients who switched from timolol therapy. Adverse events were more frequent with bimatoprost therapy.

Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. [2011.09.05]
BACKGROUND: Bimatoprost 0.03% is associated with increased growth and prominence of eyelashes. OBJECTIVE: We sought to compare the safety and efficacy of once-daily bimatoprost 0.03% versus vehicle in increasing eyelash length, thickness, and darkness after topical administration to upper eyelid margins... CONCLUSION: Bimatoprost 0.03% was found to be effective at enhancing eyelashes in adults with a very good safety profile. Copyright (c) 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

more studies >>

Clinical Trials Related to Lumigan (Bimatoprost)

Safety and Efficacy Assessment of Monoprost� in Comparison With Lumigan� 0.01 % and Lumigan� 0.03% Unit Dose [Recruiting]
Primary objective: The primary objective is to demonstrate the superiority of Monoprost versus Lumigan 0. 01% and Lumigan 0. 03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse eye at Day 84. The conjunctival hyperaemia will be scored using the MacMonnies photographic scale (0 to 5).

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes [Completed]
Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1: 1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. Results: The average eyelash growth in the Lumigan group was 2. 01mm (vs. control average of 1. 13mm) which was a statistically significant difference (p=0. 009). The average intraocular pressure decreased equally in both groups (2. 14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata [Completed]
This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day.

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye [Active, not recruiting]

Comparing Safety and Efficacy of Combigan and Lumigan With Lumigan Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan [Completed]
Comparing Safety and Efficacy of Combigan and Lumigan with Lumigan Alone in Glaucoma or Ocular Hypertension Subjects Treated with Xalatan.

more trials >>

Reports of Suspected Lumigan (Bimatoprost) Side Effects

Ocular Hyperaemia (61)Eye Irritation (60)Eye Pain (40)Headache (29)Drug Ineffective (24)Growth of Eyelashes (24)Eye Pruritus (24)Intraocular Pressure Increased (23)Vision Blurred (23)Visual Acuity Reduced (18)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 12 ratings/reviews, Lumigan has an overall score of 8.25. The effectiveness score is 8.83 and the side effect score is 8.17. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Lumigan review by 35 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   o increase length and fullness of eyelashes
Dosage & duration:   Apply to eyelashes (dosage frequency: once per day) for the period of Four months
Other conditions:   N/A
Other drugs taken:   N/A
  
Reported Results
Benefits:   My eyelashes grew extremely long.
Side effects:   If I got any of the product on my eyelids, it stained them purple.
Comments:   This was prescribed off-label to me. It is a potent glaucoma drug. It is essential that you not get it in your eyes or on your eyelids. It only needs to be painted on the eyelashes, away from the eyelids, to be effective. Results were seen within a month.

 

Lumigan review by 49 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Longer eyelashes
Dosage & duration:   once thin strip on eyelashes nightly (dosage frequency: once a night) for the period of 3 months
Other conditions:   itchy eyelids
Other drugs taken:   only vitamins
  
Reported Results
Benefits:   The Lumigan made my lashes grown longer and thicker. I didn't need to use as much mascara.
Side effects:   I got itchy eyelids. The itching was fairly mild.
Comments:   I put a drop of lumigan on an upside down teacup. Then I applied lumigan with a very fine artists type paintbrush. I would paint a thin line just above the lashes on top and just below the lashes on bottom. I would then use the remainder on my eyebrows. After about 6 weeks I noticed my lashes were longer and thicker. I washed the paintbrush carefully after each use and was careful to keep the line thin. After the first week, I began to use it every other night.

 

Lumigan review by 34 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Eyelash growth
Dosage & duration:   One or two drops along the lash line (dosage frequency: once a day) for the period of One month
Other conditions:   None
Other drugs taken:   Birth Control pills
  
Reported Results
Benefits:   The upper and lower eyelashes grew longer, thicker, and darker. There is less need for mascara or eyelash curlers with this product. Lumigan contains the same active ingredient that Latisse will contain when it is released but the difference is that Lumigan is prescribed as a glaucoma medication while Latisse will be marketed and sold as an eyelash growth product. It does work.
Side effects:   I developed dark under eye circles, itching, redness and a slight headache after each use but I was told that the under eye circles and headaches I experienced were less common side effects. Once the treatment was stopped all of the side effects disappeared including the dark under eye circles. Also, once the treatment is stopped the eyelashes eventually return to their original state.
Comments:   I was told to use it once a day at night and to apply it with clean brush. It is important to try to keep the bottle from having direct contact with the skin in order to avoid contamination. I used a new eyelash brush daily and Latisse contains once a day applicators.

See all Lumigan reviews / ratings >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017